If you have searched retatrutide price Australia in the past few weeks, you will have noticed something odd: plenty of numbers, no actual price. That is because retatrutide has no Australian price to quote. It is an investigational Eli Lilly molecule — a triple agonist hitting GLP-1, GIP and glucagon receptors — and Lilly told investors in July 2026 that it now expects to file for approval with the US FDA in the first quarter of 2027, having needed more time to assemble manufacturing and quality-control data.

So instead of guessing at a figure, it is worth looking at the two gates any obesity medicine has to pass before an Australian pays a subsidised price for it — and at what happened this year when Lilly's existing triple-threat product reached the second gate.

Retatrutide price in Australia: why no figure exists yet

Two separate decisions set what an Australian pays for a prescription medicine, and they are made by different bodies.

Gate one is the TGA. Registration on the Australian Register of Therapeutic Goods is what makes a medicine legally marketable here. Retatrutide has not been registered, and Lilly's stated global filing plan starts in Q1 2027. Until a sponsor lodges a dossier and the TGA completes its evaluation, there is no product, no approved indication and no list price. We cover the status in more detail on our TGA and Australia page and what retatrutide actually is.

Gate two is the PBS. TGA registration only means a medicine can be sold. Whether it is subsidised is a separate question decided after the Pharmaceutical Benefits Advisory Committee (PBAC) assesses cost-effectiveness and the sponsor and the Commonwealth agree on price. That second gate is where the interesting Australian evidence sits right now.

The PBS gate: what happened to Lilly's tirzepatide in 2026

Tirzepatide — the dual GLP-1/GIP agonist sold as Mounjaro and Zepbound, and retatrutide's closest structural relative — is a useful case study because it cleared gate one years ago.

At its March 2026 meeting, the PBAC recommended listing tirzepatide on the PBS for adults with inadequately controlled type 2 diabetes. That recommendation followed three earlier knock-backs.

Then, in April 2026, Lilly Australia said it would not proceed. As reported by the RACGP's newsGP, the company said the reimbursement conditions offered were not acceptable, describing the government's price terms as unrealistic and unviable, and Lilly put the number of Australians with type 2 diabetes affected by the decision at around 450,000.

The PBS's own Medicine Status record for tirzepatide reflects the outcome in administrative language: the medicine is not listed, and the listing process has ceased because the sponsor did not proceed. A positive PBAC recommendation, in other words, is necessary but not sufficient. The price has to be agreed as well.

What the PBAC has actually said about GLP-1s for obesity

The other half of the Australian cost picture is that obesity itself has historically not been a subsidised indication here.

In March 2025, Health Minister Mark Butler asked the PBAC for advice on equitable access to GLP-1 obesity treatments through the PBS. The PBAC's resulting advice, published by the Department of Health, set out a deliberately staged approach: begin with the highest-risk groups most likely to benefit — specifically, people with obesity and established cardiovascular disease — and expand only as evidence and budget questions are resolved. The committee explicitly favoured a "slow and managed" rollout, citing concerns about prescribing outside approved criteria and uncertainty about long-term use, outcomes and cost.

That advice is about semaglutide 2.4 mg, not retatrutide. But it is the clearest public statement we have of how Australian subsidy for this drug class is being framed: narrow first, broad later, and never simply "obesity" as an open-ended criterion.

What this does and does not tell us about retatrutide

Being honest about the limits here matters more than a confident-sounding prediction.

What the record shows: retatrutide is not TGA-registered; no PBAC submission for it exists; no Australian price exists; and the most recent Australian reimbursement decision involving this drug class and this manufacturer ended with no listing.

What the record does not show: any retatrutide-specific timeline, price point or listing outcome. A future retatrutide dossier would be assessed on its own clinical evidence, its own comparator, its own economics and its own commercial negotiation. None of that has begun, and anyone quoting you an Australian dollar figure for retatrutide today is not quoting a real one.

The clinical case, meanwhile, keeps getting stronger — TRIUMPH-1 reported up to about 28.3% average body weight loss at 12 mg over 80 weeks, with 45.3% of participants losing 30% or more, and you can read the trial detail on our clinical trials page. Strong efficacy data does not automatically translate into a subsidised price, as tirzepatide's 2026 experience demonstrates. Tolerability is the other half of any real-world cost conversation, and we summarise the reported adverse-event profile on our safety page.

With roughly 66.8% of Australian adults living overweight or obese, the gap between "a drug works" and "a drug is affordable here" is the part worth watching.

Want the next Australian regulatory or reimbursement development as it lands? Join the free retatrutide updates list — no cost, no spam.

FAQ

How much will retatrutide cost in Australia?

There is no Australian price, because retatrutide is investigational and not registered by the TGA. Lilly has said it expects to begin filing for approval with the FDA in the first quarter of 2027, and no PBS submission exists here.

Will retatrutide be listed on the PBS?

It cannot be considered for PBS listing until it is registered in Australia and a sponsor makes a submission to the PBAC, neither of which has happened. The relevant precedent is cautionary: the PBAC recommended tirzepatide for type 2 diabetes in March 2026 and it still was not listed.

Why isn't Mounjaro on the PBS for type 2 diabetes?

The PBAC recommended tirzepatide at its March 2026 meeting, but Lilly Australia declined to proceed in April 2026, saying the government's price conditions were unrealistic and unviable. The PBS Medicine Status record now shows the listing process as ceased because the sponsor did not proceed.

Is any weight-loss medicine subsidised on the PBS?

Following a request from the Health Minister, the PBAC advised a staged approach to subsidised GLP-1 access for obesity, starting with people who have obesity plus established cardiovascular disease and expanding only gradually. The committee described this as a deliberately "slow and managed" rollout.

Sources

This article is general information, not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Speak with a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.